Clinical trial Recruiting at 1 site Interventional Ages 50 to 85

Deep-learning ECG to detect pulmonary hypertension

Official title: A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension: A Randomized Controlled Trial

Run by National Defense Medical Center, Taiwan · NCT07079592 · Data updated 2026-11-12

This trial tests whether an AI-powered ECG can spot high blood pressure in the lungs (pulmonary hypertension) in adults aged 50–85 who have had a recent ECG.

Quick facts

Study typeInterventional
Ages50 Years to 85 Years
SexAll
Enrollment8666 (estimated)
SponsorNational Defense Medical Center, Taiwan
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedFebruary 2026
Main results expectedJune 15, 2026
Study endsJune 15, 2026
Registry record updatedFebruary 24, 2026
Trial IDNCT07079592 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 50–85 years old who have had at least one 12‑lead ECG within the last three months and do not have a prior diagnosis of pulmonary hypertension, excluded cardiomyopathies, or prior heart/lung transplants.

Probably not a fit

Patients with an existing diagnosis of pulmonary hypertension, certain cardiomyopathies, prior heart or lung transplants, very high previously measured pulmonary pressures, or without a recent ECG are unlikely to benefit from this screening approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study applies a deep-learning algorithm to routine 12-lead ECGs to screen for elevated pulmonary arterial pressure in older adults. Participants aged 50–85 with a 12-lead ECG within the prior three months will have the AI-ECG analyzed to identify likely elevated PAP. Those flagged by the algorithm would be prompted to undergo echocardiography for confirmation and potential clinical follow-up. The protocol excludes patients with known pulmonary hypertension, certain cardiomyopathies, prior heart or lung transplants, or very high prior echocardiographic pressures to focus on undiagnosed or high-risk cases.

Why it matters

Potential benefit: If successful, this approach could enable earlier, noninvasive detection of pulmonary hypertension and lead to faster diagnostic workups and potentially better outcomes.

How similar studies have gone: Earlier reports have shown promising results for AI-ECG algorithms in detecting elevated pulmonary arterial pressure and predicting cardiovascular outcomes, but broader validation is still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men or women, ≥ 50 to 85 years of age
* At least one 12-lead ECG within 3 months

Exclusion Criteria:

* A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5
* A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
* Prior heart, lung, or heart-lung transplants
* Any systolic pulmonary artery pressure \>50 mmHg by echocardiography before
* Echocardiography in 3 months before index ECG

Where it's running

  • National Defense Medical Center
    Taipei, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.